A closer look at “L'Oreal CEO: Weight Loss Drugs Like GLP-1s Are Hitting Beauty and Skin Care Sales”, exactly as the source publishes it. L'Oreal, the world's largest beauty company, has acknowledged that the rising use of GLP-1 weight loss drugs is affecting its sales in beauty and skin care. CEO Nicolas Hieronimus called the trend "a very important phenomenon for us," signaling that the drugs' impact on consumer behavior is becoming a significant factor for the cosmetics industry.
The company did not provide specific sales figures tied to GLP-1 usage, but the statement marks a notable shift in how major beauty brands view the weight loss medication boom. GLP-1 drugs, such as Ozempic and Wegovy, have surged in popularity for their appetite-suppressing and weight-reducing effects, leading to changes in how consumers spend on personal care. This listing links straight to the original page, where the content is available in full.